Talis Biomedical Corp Cashflow Statement

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Depreciation and amortization
Non-cash lease expense
Impairment of long-lived assets
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Prepaid research and development
Other long-term assets and liabilities
Other long-term assets
Accounts payable
Accrued expenses and other liabilities
Lease liabilities
Net cash used in operating activities
Investing activities
Purchase of property and equipment, net
Net cash used in investing activities
Financing activities
Proceeds from stock option exercises
Proceeds from stock issuances pursuant to employee stock purchase plan
Proceeds from initial public offering, net of issuance costs
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalent and restricted cash at end of year
Supplemental disclosure of noncash activities
Property and equipment purchases included in accounts payable and accrued expenses
Right-of-use assets obtained in exchange for operating lease liabilities
Remeasurement of operating lease right-of-use asset for lease modification

Comments